-

FUJIFILM Biotechnologies Welcomes Samuel Hernandez as Site Head of Texas Facility

COLLEGE STATION, Texas--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, is pleased to announce the appointment of Samuel Hernandez, Ph.D., as senior vice president and site head for its College Station, Texas facility, effective Monday, August 25. With over two decades of biotechnology and pharmaceutical leadership experience, Dr. Hernandez is poised to lead the Texas site’s approximately 770-strong team to achieve continued growth of cell culture and advanced therapies offerings. The previous site head, Keita Hirabayashi, has been appointed to the position of senior director, Corporate Office and board member of the Texas site.

Dr. Hernandez joins FUJIFILM Biotechnologies from Amgen, where he recently served as executive director and head of Global Manufacturing Strategies and Technologies. In this role, he contributed to the strategy for manufacturing capacity expansion and integrated cutting-edge technologies across sites in the U.S., Puerto Rico, Europe, and Asia. His tenure as plant manager at Amgen's Juncos, Puerto Rico, site was marked by operational transformation, including the successful introduction of new products and critical partnerships, notably manufacturing a COVID-19 neutralizing antibody therapy. Dr. Hernandez has a Ph.D. in Molecular Biophysics and Biochemistry from Yale University and a B.S. in Chemistry from the University of Puerto Rico.

In his new role, Dr. Hernandez will oversee Texas site strategy, operations, talent development, and uphold FUJIFILM Biotechnologies' commitment to quality, innovation, and reliable supply for its partners.

“We are thrilled to have Sam join our team to lead our Texas site during an exciting period where we are supporting treatments to combat serious diseases such as cancers,” said Lars Petersen, president and chief executive officer, FUJIFILM Biotechnologies. “His commitment to quality and our People First culture will enable us to continue our growth journey at this site.”

“I am grateful for the opportunity to join FUJIFILM Biotechnologies, a brand with a history of innovation and excellence in manufacturing,” said Dr. Hernandez. “I am truly excited about the opportunity to lead the talented team here in Texas.”

About FUJIFILM Biotechnologies
FUJIFILM Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines and advanced therapies. With over 30 years of experience, the Company specializes in developing and manufacturing biopharmaceuticals using microbial, mammalian, and host/virus systems. With over 4,800 employees, FUJIFILM Biotechnologies operates a fully integrated, kojoXTM global network with major facilities in the United States, the United Kingdom, and Denmark, with a planned new site in Holly Springs, North Carolina, USA. The Company's kojoX manufacturing network ensures supply chain agility for its customers through modular facilities and standardized processes for seamless scaling and technology transfers. FUJIFILM Biotechnologies offers comprehensive services, ranging from proprietary cell line development, to process and analytical development, and through to clinical and commercial manufacturing. For more information, go to: fujifilmbiotechnologies.fujifilm.com

About FUJIFILM Holdings Corporation
FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of “giving our world more smiles,” we address social challenges and create a positive impact on society through our products, services, and business operations. For more information, please visit: www.fujifilmholdings.com. For further details about our commitment to sustainability and Fujifilm’s Sustainable Value Plan 2030, click here.

Contacts

Media Contacts:
Christine Jackman
FUJIFILM Biotechnologies
christine.jackman@fujifilm.com
914-261-4959

Megan Augustine
FUJIFILM Holdings America Corporation
megan.augustine.contractor@fujifilm.com

FUJIFILM Biotechnologies


Release Versions

Contacts

Media Contacts:
Christine Jackman
FUJIFILM Biotechnologies
christine.jackman@fujifilm.com
914-261-4959

Megan Augustine
FUJIFILM Holdings America Corporation
megan.augustine.contractor@fujifilm.com

Social Media Profiles
More News From FUJIFILM Biotechnologies

Fujifilm’s ELUXEO 8000® Endoscopic Imaging System in Combination with 840TP Gastroscope Wins 2026 MedTech Breakthrough Award

LEXINGTON, Ma.--(BUSINESS WIRE)--FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic imaging and endosurgical solutions, announced that its ELUXEO® 8000 Endoscopic Imaging System coupled with its EG-840TP ultra slim therapeutic gastroscope has been selected as the winner of the “Best New Endoscopy Technology Solution” award in the 10th annual MedTech Breakthrough Awards program. MedTech Breakthrough is an independent market intelligence organization that recognizes the to...

Fujifilm Develops Novel Screening Platform to Identify High-Affinity Cyclic Peptides for Challenging Membrane Protein Targets  

TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation announced today that it has developed an innovative screening methodology for cyclic peptides exhibiting high affinity toward membrane proteins1. This new technology enables Fujifilm to offer cyclic peptide discovery services targeting challenging membrane proteins, including multi-pass transmembrane proteins2, which represent complex drug targets. The results of this study are scheduled to be presented at TIDES USA, an exhibition from May 11 to 14,...

Fujifilm Government Affairs Head Elected to BIO Board of Directors

VALHALLA, N.Y.--(BUSINESS WIRE)--FUJIFILM Americas today announced that Biotechnology Innovation Organization (BIO), the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe, has welcomed Fujifilm’s Crystal Fry-Vanuch as a newly elected member of its Board of Directors for the 2026-2030 term. Fry-Vanuch serves as Head of Government Affairs for FUJIFILM America...
Back to Newsroom